{
"generated_at": "2026-07-06T18:27:42+08:00",
"market_date": "2026-07-02",
"universe_count": 2005,
"scored_count": 513,
"top": [
{
"symbol": "VRTX",
"name": "Vertex Pharmaceuticals Incorporated Common Stock",
"sector": "Health Care",
"industry": "Biotechnology: Pharmaceutical Preparations",
"exchange": "NASDAQ",
"market_cap": 134019412393.0,
"dollar_volume": 979831552.04,
"price": 528.0399780273438,
"last_date": "2026-07-02",
"return_5d": 0.09967092773871089,
"return_20d": 0.2327589824481533,
"return_60d": 0.22271105436518823,
"return_120d": 0.12425478253626232,
"ma20_distance": 0.13293972372421448,
"ma50_distance": 0.18152057644675312,
"ma200_distance": 0.18960235308143703,
"volume_ratio": 1.8288210011700785,
"volatility_20d": 0.2859331507828172,
"drawdown_52w": 0.0,
"trend_score": 1.0,
"sector_score": 0.8461538461538461,
"rs_20d": 0.2453013576337496,
"rs_60d": 0.012021197126203864,
"entry_setup_score": 0.8515526948467496,
"overheat_score": 0.0,
"breakdown": {
"technical": 21.051721169668937,
"relative_strength": 14.428015564202335,
"volume": 11.36964980544747,
"sector": 8.461538461538462,
"news": 15.328,
"liquidity": 7.645914396887159,
"risk_quality": 8.540856031128405,
"entry_setup": 6.8124215587739965,
"overheat_penalty": -0.0
},
"score": 86.82569542887276,
"items": [
{
"title": "While SpaceX Gets the Headlines, Smart Investors Are Loading Up on This Stock Instead",
"link": "https://www.nasdaq.com/articles/while-spacex-gets-headlines-smart-investors-are-loading-stock-instead",
"published": "2026-07-05",
"age_days": 1,
"source": "The Motley Fool",
"snippet": "Key PointsVertex Pharmaceuticals arguably dominates its market more than SpaceX does its markets.",
"relevance": 0.7,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Vertex Pharmaceuticals (VRTX) Wins FDA Approval To Treat Two Year Olds With CASGEVY",
"link": "https://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-vrtx-wins-fda-141453136.html?.tsrc=rss",
"published": "2026-07-03",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "FDA approved expanded use of CASGEVY for children as young as two years with sickle cell disease and transfusion-dependent beta thalassemia. The approval makes CASGEVY the first gene therapy of its kind available to this pediatric group in the U.S. Vertex Pharmaceuticals estimates that roughly 5,500 additional children in the U.S. may now be eligible for this one-time genetic treatment. Vertex Pharmaceuticals, traded as NasdaqGS:VRTX, now has FDA approval to offer CASGEVY to a much younger...",
"relevance": 2.0,
"category": "医药/审批",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 2.0,
"negative_hits": 0.0
},
{
"title": "Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?",
"link": "https://finance.yahoo.com/markets/stocks/articles/wall-street-bulls-look-optimistic-133007390.html?.tsrc=rss",
"published": "2026-07-03",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
"relevance": 1.6500000000000001,
"category": "分析师/评级",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT",
"link": "https://finance.yahoo.com/healthcare/articles/vertex-gets-fda-nod-expanded-144200647.html?.tsrc=rss",
"published": "2026-07-02",
"age_days": 3,
"source": "Yahoo Finance",
"snippet": "VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.",
"relevance": 1.6500000000000001,
"category": "产品/订单",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "CRSP, VRTX Stocks Surge As FDA Clears Casgevy For Children Ages 2 And Up",
"link": "https://stocktwits.com/news-articles/markets/equity/crsp-vrtx-stocks-surge-as-fda-clears-casgevy-for-children-ages-2-and-up/cZmexkXR7je?.tsrc=rss",
"published": "2026-07-02",
"age_days": 3,
"source": "Yahoo Finance",
"snippet": "The fresh FDA approval allows the use of the cell therapy in patients as young as two years old with sickle cell disease (SCD) who have recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT).",
"relevance": 1.3,
"category": "医药/审批",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 2.0,
"negative_hits": 0.0
},
{
"title": "VRTX rises after CASGEVY label expansion broadens patient reach",
"link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOVkE1YmZkSEQ5QnU3b0NWVXlOY1lpOVZIRmtDT2I1bGpZZGM2cEtWMk4wX3ZDTi1lYzdFS3Z6b0I4UkR1dkVhZmxIaGtQeE9JZUJhQ1k1eTZabG5DWnFCbGRkU1c1Y0Y3VVRCbXVacHB1TlQxYXdJNkRKWEFtVXpBcExsZDZ3LXcwV0I5TlM3bG03eDBXdERfaHdGOGM?oc=5",
"published": "2026-07-02",
"age_days": 3,
"source": "Quiver Quantitative",
"snippet": "VRTX rises after CASGEVY label expansion broadens patient reach Quiver Quantitative",
"relevance": 1.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "QQEW, AXON, VRTX, ABNB: ETF Outflow Alert",
"link": "https://www.nasdaq.com/articles/qqew-axon-vrtx-abnb-etf-outflow-alert",
"published": "2026-07-02",
"age_days": 4,
"source": "BNK Invest",
"snippet": "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust NASDAQ-100 Equal Weighted Index Fund (Symbol: QQEW) where we have detected an approximate $358.1 million dollar outflow -- that's a 16.5",
"relevance": 1.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal",
"link": "https://www.nasdaq.com/articles/weekly-buzz-vrtx-aptx-gain-fda-nod-uncy-disappoints-ipsen-opens-wallet-vtgn-misses-goal",
"published": "2026-07-02",
"age_days": 4,
"source": "RTTNews",
"snippet": "(RTTNews) - The holiday-shortened week delivered no shortage of action for the biotech sector, with a mix of FDA, China, Canada, and EU approvals, acquisitions, and positive clinical readouts, alongside regulatory rejections, program discontinuations, and trial goal misses.",
"relevance": 1.0,
"category": "医药/审批",
"sentiment": "negative",
"freshness": 0.65,
"positive_hits": 1.0,
"negative_hits": 2.0
},
{
"title": "Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade) (VRTX)",
"link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOaXd1cVRJTG5BTTlvSWRTSTVaRDZBOFJZT1dicm1FMUNsb21LVXdPN2tJZnYzVjRlRjRRbzZreC14UmUtajd6UnRNQm5yMlNEaHJGVXE5bnFYTzdRS2RpT3ZXVWlqQlZTTzcwVWYtOVlrMkFuclJtMFVXby1OY3RlbnpYbUJsQUMzSG40bGRISVlLekRvUjBaaVVBMXhsNnNYSzBISzdQaEhUQzZBb1k5WXgzVzBPZkRLZTlaZWtB?oc=5",
"published": "2026-06-24",
"age_days": 12,
"source": "Seeking Alpha",
"snippet": "Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade) (VRTX) Seeking Alpha",
"relevance": 1.7,
"category": "分析师/评级",
"sentiment": "positive",
"freshness": 0.3,
"positive_hits": 2.0,
"negative_hits": 0.0
}
],
"news_score": 0.958,
"positive_hits": 6.25,
"negative_hits": 1.3,
"news_sources": [
"BNK Invest",
"Quiver Quantitative",
"RTTNews",
"Seeking Alpha",
"The Motley Fool",
"Yahoo Finance"
],
"catalysts": [
"产品/订单",
"分析师/评级",
"医药/审批",
"市场观点"
],
"news_errors": []
},
{
"symbol": "LLY",
"name": "Eli Lilly and Company Common Stock",
"sector": "Health Care",
"industry": "Biotechnology: Pharmaceutical Preparations",
"exchange": "NYSE",
"market_cap": 1143189310157.0,
"dollar_volume": 4001318061.9300003,
"price": 1213.9100341796875,
"last_date": "2026-07-02",
"return_5d": 0.0764572686228977,
"return_20d": 0.12526187101450814,
"return_60d": 0.3037515161443356,
"return_120d": 0.11861526527479116,
"ma20_distance": 0.05831174924669247,
"ma50_distance": 0.1507106975942576,
"ma200_distance": 0.2323756388981153,
"volume_ratio": 1.2499148033385272,
"volatility_20d": 0.34396983752328286,
"drawdown_52w": -0.013025146822711164,
"trend_score": 1.0,
"sector_score": 0.8461538461538461,
"rs_20d": 0.13780424620010445,
"rs_60d": 0.09306165890535123,
"entry_setup_score": 1.0,
"overheat_score": 0.0,
"breakdown": {
"technical": 21.811284046692606,
"relative_strength": 14.330739299610894,
"volume": 8.171206225680933,
"sector": 8.461538461538462,
"news": 16.0,
"liquidity": 9.455252918287938,
"risk_quality": 7.480544747081712,
"entry_setup": 8.0,
"overheat_penalty": -0.0
},
"score": 85.71056569889254,
"items": [
{
"title": "Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.)",
"link": "https://www.fool.com/investing/2026/07/06/could-buying-eli-lilly-stock-today-set-you-up-for/?.tsrc=rss",
"published": "2026-07-06",
"age_days": 0,
"source": "Yahoo Finance",
"snippet": "Lilly offers investors safety and growth.",
"relevance": 2.0,
"category": "市场观点",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "Lilly quietly hands Chinese partner its cancer drug",
"link": "https://www.thestreet.com/investing/stocks/lly-eli-lilly-innovent-verzenios-china-deal?.tsrc=rss",
"published": "2026-07-06",
"age_days": 0,
"source": "Yahoo Finance",
"snippet": "Eli Lilly (LLY) climbed to new record highs in the final week of June, driven by strong sales of its weight-loss drugs. Away from that spotlight, the drugmaker made changes to a smaller corner of its business in its second-largest market. On June 30, Lilly agreed to hand a Chinese partner full ...",
"relevance": 1.6500000000000001,
"category": "医药/审批",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 2.0,
"negative_hits": 0.0
},
{
"title": "DKSH Signs Distribution And Promotion Agreement With Eli Lilly And Co In Hong Kong, Macau",
"link": "https://www.nasdaq.com/articles/dksh-signs-distribution-and-promotion-agreement-eli-lilly-and-co-hong-kong-macau",
"published": "2026-07-06",
"age_days": 0,
"source": "RTTNews",
"snippet": "(RTTNews) - DKSH Holding AG (DKSH.SW, DKSH), a Swiss market expansion services provider, on Monday has entered into a distribution and promotion agreement with Eli Lilly and Co. (LLY) to sell, promote and distribute Lilly's pharmaceutical products in Hong Kong and Macau.",
"relevance": 1.35,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Eli Lilly (LLY) Stock May Trade At A Cash Flow Discount But An Earnings Premium",
"link": "https://finance.yahoo.com/markets/stocks/articles/eli-lilly-lly-stock-may-031647120.html?.tsrc=rss",
"published": "2026-07-05",
"age_days": 1,
"source": "Yahoo Finance",
"snippet": "Eli Lilly stock has surged over the past five years, and at around US$1,213 a share, investors are weighing a sharp share price gain against signals that the stock screens as expensive on several checks even as a Discounted Cash Flow (DCF) estimate points to upside. A roughly 441.5% return over five years puts Eli Lilly among the stronger long term performers, which raises the bar for what counts as an attractive entry point. Expectations around the GLP-1 obesity and diabetes franchise can...",
"relevance": 2.0,
"category": "业绩/指引",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 3.0,
"negative_hits": 0.0
},
{
"title": "Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly",
"link": "https://247wallst.com/investing/2026/07/04/dividend-king-vs-growth-giant-johnson-johnson-takes-on-eli-lilly/?.tsrc=rss",
"published": "2026-07-04",
"age_days": 1,
"source": "Yahoo Finance",
"snippet": "Eli Lilly (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare. Lilly is riding a GLP-1 wave. JNJ is proving that a wide, refreshed portfolio can still compound. Both raised guidance and both are worth putting side by side right now. GLP-1 Fireworks ... Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly",
"relevance": 1.6500000000000001,
"category": "业绩/指引",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 3.0,
"negative_hits": 0.0
},
{
"title": "Why Is LLY Stock Rising Today?",
"link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQU3lwOWVoSUtIdndxWFhJQ0NOZG52dXNRU3o5SzktSEJWdjJTdjZ3VVVGT3hJOUgyazdubEladkxoV3hvcERqeHNKRWZxSC10VE9RVDBrUFBCNFA3R28zRmNOQW52d0JydGpPcTNsQzNFZ3VMRG5LeDRLRHUyb2lSX052a01nSlcyMFBfR2ZUXzdRWlNGZG9uQ2JwUHptcm80Z0VRbks1MXdyNldKVEJUalJBSEtiNnpSU2lIVzlB?oc=5",
"published": "2026-07-05",
"age_days": 1,
"source": "Stocktwits",
"snippet": "Why Is LLY Stock Rising Today? Stocktwits",
"relevance": 1.35,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Eli Lilly stock jumps on retatrutide Phase 3 weight loss results",
"link": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPV2ZDaDdTal93bFE0NExVMDVYNTY5UDcyMjk3ZE56YXZxSm1VWURnNjlMX3YydEtINzFZaU1wRVhjdDhsaFVwM01oa3VvRFpPc0pIaE1UMUY0VkxNYldORHZNdGRTYTRMVHJVLVh2Tjh2R0Zza3NqWUpQQ29xYndIWVYwMA?oc=5",
"published": "2026-07-04",
"age_days": 2,
"source": "qz.com",
"snippet": "Eli Lilly stock jumps on retatrutide Phase 3 weight loss results qz.com",
"relevance": 1.7,
"category": "业绩/指引",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?",
"link": "https://www.nasdaq.com/articles/johnson-johnson-walking-away-100-billion-obesity-market-could-actually-make-it-better-long",
"published": "2026-07-03",
"age_days": 3,
"source": "The Motley Fool",
"snippet": "Key PointsJohnson & Johnson's CEO recently explained that his company isn't going to get caught up in the GLP-1 weight loss drug race.",
"relevance": 1.7,
"category": "医药/审批",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Why Is Eli Lilly (LLY) Stock Soaring Today",
"link": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPWEFSdmxTaXgxejNjdFFwZkdoZkFFWlp0T0FSNnVHWFhHN1hTdnRLZEJzbzJNMi1kSXRRUDhOMzJmMHdfeGttWXRnQ1RUUUZDSnhtV0lKRU1TZTZCUUVGTy1lN2hCZnNkellGUklqVDVhZFlsODFqVGxhbTJBcDJNZXFPSXdYRm5QRkZQbg?oc=5",
"published": "2026-06-26",
"age_days": 10,
"source": "Yahoo Finance",
"snippet": "Why Is Eli Lilly (LLY) Stock Soaring Today Yahoo Finance",
"relevance": 2.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
}
],
"news_score": 1.0,
"positive_hits": 10.0,
"negative_hits": 0.0,
"news_sources": [
"RTTNews",
"Stocktwits",
"The Motley Fool",
"Yahoo Finance",
"qz.com"
],
"catalysts": [
"业绩/指引",
"医药/审批",
"市场观点"
],
"news_errors": []
},
{
"symbol": "V",
"name": "Visa Inc.",
"sector": "Consumer Discretionary",
"industry": "Business Services",
"exchange": "NYSE",
"market_cap": 686043681268.0,
"dollar_volume": 3554179204.5,
"price": 362.1300048828125,
"last_date": "2026-07-02",
"return_5d": 0.09563722897205196,
"return_20d": 0.15918697809836213,
"return_60d": 0.19692619234416764,
"return_120d": 0.028106616664383743,
"ma20_distance": 0.09414090844316259,
"ma50_distance": 0.11092978850180701,
"ma200_distance": 0.10105017209243106,
"volume_ratio": 1.3078802640629883,
"volatility_20d": 0.21408835453047115,
"drawdown_52w": 0.0,
"trend_score": 0.8,
"sector_score": 0.6153846153846154,
"rs_20d": 0.17172935328395844,
"rs_60d": -0.01376366489481673,
"entry_setup_score": 1.0,
"overheat_score": 0.0,
"breakdown": {
"technical": 20.71011673151751,
"relative_strength": 13.649805447470817,
"volume": 8.964980544747082,
"sector": 6.153846153846154,
"news": 16.0,
"liquidity": 9.416342412451362,
"risk_quality": 9.309338521400779,
"entry_setup": 8.0,
"overheat_penalty": -0.0
},
"score": 84.20442981143368,
"items": [
{
"title": "3 No-Brainer Stocks to Buy in July and Hold Forever",
"link": "https://247wallst.com/investing/2026/07/05/3-no-brainer-stocks-to-buy-in-july-and-hold-forever/?.tsrc=rss",
"published": "2026-07-05",
"age_days": 0,
"source": "Yahoo Finance",
"snippet": "July sets up as a rare buying window for forever holders. Two of the three mega-caps below are trading well off their 52-week highs, and the third just reported its best March quarter in company history. The thesis here is durability: cloud and AI scale at Microsoft, the global payments toll-booth at Visa, and Apple’s ... 3 No-Brainer Stocks to Buy in July and Hold Forever",
"relevance": 1.3,
"category": "业绩/指引",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Coinbase (COIN) Joins Visa And Mastercard To Launch Open Standard Stablecoin Network",
"link": "https://finance.yahoo.com/markets/crypto/articles/coinbase-coin-joins-visa-mastercard-061127820.html?.tsrc=rss",
"published": "2026-07-05",
"age_days": 1,
"source": "Yahoo Finance",
"snippet": "Coinbase Global (NasdaqGS:COIN) has teamed up with Visa and Mastercard to launch the Open Standard stablecoin network, including a new USD-backed stablecoin. The collaboration focuses on using stablecoins for everyday payments across card networks and digital wallets. Coinbase has also become one of the largest corporate political spenders in the 2026 U.S. midterm elections, targeting crypto-related policy and regulation. Coinbase Global enters this phase with a share price of $165.48 and a...",
"relevance": 1.3,
"category": "产品/订单",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "Rezolve AI (RZLV) is One of the Best New Tech Stocks to Buy According to Analysts",
"link": "https://finance.yahoo.com/technology/ai/articles/rezolve-ai-rzlv-one-best-132236568.html?.tsrc=rss",
"published": "2026-07-04",
"age_days": 1,
"source": "Yahoo Finance",
"snippet": "Rezolve AI Limited (NASDAQ:RZLV) is one of the best new tech stocks to buy according to analysts. On June 22, Rezolve AI announced that its Reward platform is powering “Everyday Cashback,” a new Visa Card-Linked Offers program for Mashreq Bank in the UAE. This partnership allows cardholders to access automated cashback offers of up to […]",
"relevance": 1.3,
"category": "分析师/评级",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Visa Is Having a Rare Down Year. Is the Cash Flow Machine Finally a Bargain?",
"link": "https://www.fool.com/investing/2026/07/04/visa-is-having-a-rare-down-year-is-the-cash-flow-m/?.tsrc=rss",
"published": "2026-07-04",
"age_days": 1,
"source": "Yahoo Finance",
"snippet": "It's underperforming the market.",
"relevance": 1.3,
"category": "分析师/评级",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Piper Sandler Initiates Visa Inc. (V) With Overweight Rating on Payments Strength",
"link": "https://finance.yahoo.com/markets/stocks/articles/piper-sandler-initiates-visa-inc-023905920.html?.tsrc=rss",
"published": "2026-07-04",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "Visa Inc. (NYSE:V) ranks among the best fintech stocks to buy as digital payments volume surges. On June 30, Piper Sandler began coverage of Visa Inc. (NYSE:V) with an Overweight rating and a $394 price target. The firm initiated a review of the payments and consumer finance division (which includes Visa) with a “selectively constructive” […]",
"relevance": 1.3,
"category": "分析师/评级",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "A New Stablecoin Is Taking Aim at Circle's USDC. Here's What Investors Need to Know.",
"link": "https://www.nasdaq.com/articles/new-stablecoin-taking-aim-circles-usdc-heres-what-investors-need-know",
"published": "2026-07-04",
"age_days": 2,
"source": "The Motley Fool",
"snippet": "Key PointsOpen USD's revenue-sharing model is exciting, and it might be able to take market share from Circle's USDC.",
"relevance": 1.0,
"category": "业绩/指引",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "A Huge New Stablecoin Initiative Could Disrupt the Crypto Market. Here's What You Need to Know.",
"link": "https://www.nasdaq.com/articles/huge-new-stablecoin-initiative-could-disrupt-crypto-market-heres-what-you-need-know",
"published": "2026-07-04",
"age_days": 2,
"source": "The Motley Fool",
"snippet": "Key PointsA new stablecoin backed by many major financial institutions will soon be launched.",
"relevance": 1.0,
"category": "产品/订单",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "V Stock Jumps On Strong Earnings Beat Amid Credit Card Culture Boom: Announces $20B share repurchase program",
"link": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPaGRuQTI2NXI3Z1lnOEMwZldCTElqLTJLUVQ0ajBSY1RlS25Ed2JmbmJhWDB1YnBwZGxZQ1pCYzJRM3oyVjdZZXQxNjFvMWFDQ3diVFlDSXBhVzdoU0lRYm1pNFhyMVJ1bFVRdFUtRkJpV0dQckVCanJhQi12OFNXSTA0NlpVTng1S3Q1cWNKcFQ5STBqdE1IZ1hxUW1tSGZsMW54bjZ2aXloM0g3X0Q4Wkw3amtueDI5dXBTT2U2YWRqX19lZ1BvcXAtbE93V2FTYUxWc0lIaGUyajc5LWdRM09OWTdTdlljdWJfQ0hZdm96MkRfQmIxeUNkc2hjWFdU?oc=5",
"published": "2026-07-03",
"age_days": 2,
"source": "Stocktwits",
"snippet": "V Stock Jumps On Strong Earnings Beat Amid Credit Card Culture Boom: Announces $20B share repurchase program Stocktwits",
"relevance": 1.0,
"category": "业绩/指引",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 3.0,
"negative_hits": 0.0
},
{
"title": "Visa Stock Gained 5% in 2026. Can It Bring More Meaningful Upside?",
"link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQOFpkb0N2UmU1bjl6M2RSbkQtOURCU0tmUUVwVGc5TGRDSnNtYW0wYjlRMHNUdzNFVkYwSTdNNnUxb1RqdUE1YVdTaW9mNWN5VzdrSHd2b1lBV0RhUmQ0MHJMeG1xUktpc2h0NlVOcWhGeExONGdvcDgzM2UzSGMweHRsX0tRS09Wb0hXQUhFenVrclk?oc=5",
"published": "2026-07-03",
"age_days": 2,
"source": "TIKR.com",
"snippet": "Visa Stock Gained 5% in 2026. Can It Bring More Meaningful Upside? TIKR.com",
"relevance": 1.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
}
],
"news_score": 1.0,
"positive_hits": 6.0,
"negative_hits": 0.0,
"news_sources": [
"Stocktwits",
"TIKR.com",
"The Motley Fool",
"Yahoo Finance"
],
"catalysts": [
"业绩/指引",
"产品/订单",
"分析师/评级"
],
"news_errors": []
},
{
"symbol": "ABBV",
"name": "AbbVie Inc. Common Stock",
"sector": "Health Care",
"industry": "Biotechnology: Pharmaceutical Preparations",
"exchange": "NYSE",
"market_cap": 461256601778.0,
"dollar_volume": 1856926164.6399999,
"price": 261.07000732421875,
"last_date": "2026-07-02",
"return_5d": 0.07374355506942432,
"return_20d": 0.20236725212216133,
"return_60d": 0.2650579711259371,
"return_120d": 0.16481506998904738,
"ma20_distance": 0.11708731310683129,
"ma50_distance": 0.1941703832659072,
"ma200_distance": 0.1759306408125636,
"volume_ratio": 2.152532505169934,
"volatility_20d": 0.36351565965587906,
"drawdown_52w": 0.0,
"trend_score": 0.8,
"sector_score": 0.8461538461538461,
"rs_20d": 0.21490962730775764,
"rs_60d": 0.05436811388695273,
"entry_setup_score": 0.9106696142802752,
"overheat_score": 0.0,
"breakdown": {
"technical": 20.631660416187724,
"relative_strength": 14.784046692607003,
"volume": 11.859922178988327,
"sector": 8.461538461538462,
"news": 11.408000000000001,
"liquidity": 8.715953307392997,
"risk_quality": 7.54863813229572,
"entry_setup": 7.285356914242201,
"overheat_penalty": -0.0
},
"score": 83.40975918901023,
"items": [
{
"title": "Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks",
"link": "https://finance.yahoo.com/healthcare/articles/q1-earnings-highlights-abbvie-nyse-204206648.html?.tsrc=rss",
"published": "2026-07-03",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.",
"relevance": 2.0,
"category": "业绩/指引",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "AbbVie (ABBV) Faces Congressional Probe Over China Clinical Trials",
"link": "https://finance.yahoo.com/healthcare/articles/abbvie-abbv-faces-congressional-probe-231045102.html?.tsrc=rss",
"published": "2026-07-03",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "U.S. lawmakers have opened a bipartisan national security investigation into AbbVie (NYSE:ABBV) and other pharmaceutical companies. The inquiry focuses on AbbVie’s clinical trials in China, including work at facilities reportedly linked to the Chinese military and sites in the Xinjiang region. Congress has requested detailed information on research practices, data protection, and site vetting, with responses due by mid-July. AbbVie is a large U.S. pharmaceutical company with a portfolio...",
"relevance": 1.6500000000000001,
"category": "医药/审批",
"sentiment": "negative",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 2.0
},
{
"title": "Top Research Reports for Applied Materials, Mastercard & AbbVie",
"link": "https://finance.yahoo.com/markets/stocks/articles/top-research-reports-applied-materials-204700852.html?.tsrc=rss",
"published": "2026-07-02",
"age_days": 3,
"source": "Yahoo Finance",
"snippet": "Applied Materials is riding AI-driven chip demand, but can record margins, new products and China-related risks shape its next phase of growth?",
"relevance": 1.6500000000000001,
"category": "医药/审批",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 2.0,
"negative_hits": 0.0
},
{
"title": "J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?",
"link": "https://www.nasdaq.com/articles/jj-or-abbvie-which-stock-deserves-place-your-portfolio-now",
"published": "2026-07-02",
"age_days": 4,
"source": "Zacks",
"snippet": "JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.",
"relevance": 1.7,
"category": "市场观点",
"sentiment": "positive",
"freshness": 0.65,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?",
"link": "https://www.nasdaq.com/articles/pharmaceutical-giant-just-poured-11-billion-acquisition-time-buy",
"published": "2026-06-30",
"age_days": 6,
"source": "The Motley Fool",
"snippet": "Key PointsAbbVie recently announced an acquisition that may help it remain a leader in immunology.",
"relevance": 1.35,
"category": "并购/资本",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising",
"link": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPc0tVT0o5Q0piVzBQakZ0QkZXOXJPbjBRNGg3SUt4NHZUeXh6QU1vQzRpdWRTMTllM0h4NDFWTS1rMGNrU1NhSV9RVFNxdnVUZHQyV2FSMzU4bVlXS0RxRUowd3NSQjdaTGJnaURZR0VOdWwxMWRjRWRsYm12R0FOZmdn?oc=5",
"published": "2026-06-22",
"age_days": 14,
"source": "Barron's",
"snippet": "Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising Barron's",
"relevance": 1.7,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Why AbbVie Stock Jumped Today",
"link": "https://news.google.com/rss/articles/CBMie0FVX3lxTE5VOHIwU1RTQmlvMF9BT0VaNC1xd3hxTzV2cDF2bkFjZjhnM3BYYjVNU0hBanktZWRoYS1QTUZveHludjQ2SGlxYmdxRFpQWkZxbUJ0NG5YLVRvNG1FYjdZOXNGLVQ0cjhKN3hkZTlfY2ZvRi1XQjNjelhBZw?oc=5",
"published": "2026-06-22",
"age_days": 14,
"source": "The Motley Fool",
"snippet": "Why AbbVie Stock Jumped Today The Motley Fool",
"relevance": 1.7,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "AbbVie Goes On The Offensive With $10.9 Billion Takeover",
"link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNM01TYno1alhZU0J0bTF6NEdGdTlpY0ltTVdMekluZ3ZGdWZncHRmT2NlY2hZS3NiZUVIM0w2bmJQUUZyQ0E0RFFVdE4tODg0QjlIM1VtVnVTMXJPRlhfTnFKM19FclJzb2lVaG84WE5IRFAzaFRLUTVTbFlXRUVWWl9lUnFzSFduVGdvRUk3OUc3aDBzZFBuTXln?oc=5",
"published": "2026-06-22",
"age_days": 14,
"source": "Investor's Business Daily",
"snippet": "AbbVie Goes On The Offensive With $10.9 Billion Takeover Investor's Business Daily",
"relevance": 1.35,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics",
"link": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOZWlQaFAxMGsxVk5HTFYtc0taSWY2WFZXeVl4Ulc1Q29rZFI5REU0Qk12N2VGMFRXVmJXZFZNbXNaNUhsNXRlRlR2OU1CV28zbGdvMU9UcjdDMERLOEJXbE9hNGEwdUZwSnVHN1JGOXNYajkwd0tKeW9FdmIwVlBOMEhxSF8?oc=5",
"published": "2026-06-19",
"age_days": 17,
"source": "Financial Times",
"snippet": "AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics Financial Times",
"relevance": 1.35,
"category": "产品/订单",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
}
],
"news_score": 0.7130000000000001,
"positive_hits": 2.65,
"negative_hits": 2.0,
"news_sources": [
"Barron's",
"Financial Times",
"Investor's Business Daily",
"The Motley Fool",
"Yahoo Finance",
"Zacks"
],
"catalysts": [
"业绩/指引",
"医药/审批",
"市场观点",
"并购/资本"
],
"news_errors": []
},
{
"symbol": "MNST",
"name": "Monster Beverage Corporation",
"sector": "Consumer Staples",
"industry": "Beverages (Production/Distribution)",
"exchange": "NASDAQ",
"market_cap": 95453591536.0,
"dollar_volume": 555011769.6,
"price": 97.5999984741211,
"last_date": "2026-07-02",
"return_5d": 0.018470172276390695,
"return_20d": 0.09613653942697797,
"return_60d": 0.3473218551181818,
"return_120d": 0.2741514414924531,
"ma20_distance": 0.047047384539863124,
"ma50_distance": 0.12010611823355233,
"ma200_distance": 0.25780325545408433,
"volume_ratio": 1.1836510716731399,
"volatility_20d": 0.15983073527161776,
"drawdown_52w": -0.0004096775479044412,
"trend_score": 1.0,
"sector_score": 0.6923076923076923,
"rs_20d": 0.10867891461257428,
"rs_60d": 0.13663199787919744,
"entry_setup_score": 1.0,
"overheat_score": 0.0,
"breakdown": {
"technical": 21.45136186770428,
"relative_strength": 14.081712062256809,
"volume": 6.980544747081712,
"sector": 6.923076923076923,
"news": 15.408000000000001,
"liquidity": 5.36964980544747,
"risk_quality": 9.571984435797667,
"entry_setup": 8.0,
"overheat_penalty": -0.0
},
"score": 79.78632984136485,
"items": [
{
"title": "Morgan Stanley unveils key Monster stock price prediction",
"link": "https://www.thestreet.com/investing/stocks/morgan-stanley-unveils-key-monster-stock-prediction?.tsrc=rss",
"published": "2026-07-05",
"age_days": 1,
"source": "Yahoo Finance",
"snippet": "Monster Beverage (MNST) shares have spent the summer moving toward record highs, and Morgan Stanley just gave investors a fresh reason to keep watching. The bank reiterated its Overweight rating and $103 price target on the energy drink maker this week. Morgan Stanley is standing by a call it has ...",
"relevance": 2.0,
"category": "分析师/评级",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "Will Monster Beverage's Expansion Strategy & Innovations Aid?",
"link": "https://finance.yahoo.com/markets/stocks/articles/monster-beverages-expansion-strategy-innovations-153500418.html?.tsrc=rss",
"published": "2026-07-03",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "MNST is riding strong energy drink demand and product innovation to fuel growth while expanding its global footprint and market share.",
"relevance": 2.0,
"category": "市场观点",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 2.0,
"negative_hits": 0.0
},
{
"title": "FMX or MNST: Which Is the Better Value Stock Right Now?",
"link": "https://finance.yahoo.com/markets/stocks/articles/fmx-mnst-better-value-stock-154001845.html?.tsrc=rss",
"published": "2026-07-03",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "FMX vs. MNST: Which Stock Is the Better Value Option?",
"relevance": 1.3,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Should Investors Buy Celsius Stock Instead of Monster Stock?",
"link": "https://www.nasdaq.com/articles/should-investors-buy-celsius-stock-instead-monster-stock",
"published": "2026-07-02",
"age_days": 4,
"source": "The Motley Fool",
"snippet": "The energy drink segment is growing faster than the overall beverage market.",
"relevance": 0.7,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Monster Beverage stock hits 52-week high at $97.89",
"link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTFdFcGowbTE0dEFMdGFJVnZSUVNreFotRXREdTM0Y2NuWXNfWU1pZU9mRmJPX0pUWWIzRENRN0pBUGxYSFJTNXZPZHpfNDhPXzl6Y1FxcDgwVURpc252cDZ1S3ZUX3VEOEdUeDhmaGZ3NE5pZjFlSEJrZ3BVTjJDbHc1TGlfUUVySHl2X3dtVU13R05FdnV0MFd6NGRVV3p5bmR4RW9JMA?oc=5",
"published": "2026-07-01",
"age_days": 4,
"source": "Investing.com",
"snippet": "Monster Beverage stock hits 52-week high at $97.89 Investing.com",
"relevance": 0.7,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Monster Beverage Stock Has Outrun the Street’s Mean Target. Here’s the Fuller Picture",
"link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQTjZXN1k4RDF3OHFYWWdYSV9qRDFmV194Zk5DSXhaR0RCTkxfSXBzS1IxaW9KS0dVZWZwYzdUSjhFT3htTVd5WEpiUm4xbU5YNjFJSTdJXzB4eDRadldtc0ZIOUtoUmNEUkxlTG9TNzhKbGs3cU5vQ05pdjFuUjVKOW8wZW9lXzUxakVJX2ZDWF90WnRnUy1qQkNsUjNidlF6RDJ0MF9IZFVKVEVj?oc=5",
"published": "2026-06-29",
"age_days": 6,
"source": "TIKR.com",
"snippet": "Monster Beverage Stock Has Outrun the Street’s Mean Target. Here’s the Fuller Picture TIKR.com",
"relevance": 0.7,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "JQUA, CB, KEYS, MNST: Large Inflows Detected at ETF",
"link": "https://www.nasdaq.com/articles/jqua-cb-keys-mnst-large-inflows-detected-etf",
"published": "2026-06-29",
"age_days": 7,
"source": "BNK Invest",
"snippet": "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the JPMorgan US Quality Factor ETF (Symbol: JQUA) where we have detected an approximate $509.0 million dollar inflow -- that's a 6.4% increase week over",
"relevance": 1.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Morgan Stanley Sees Red Bull Price Increase as Positive for Monster Beverage (MNST)",
"link": "https://finance.yahoo.com/markets/stocks/articles/morgan-stanley-sees-red-bull-000827937.html?.tsrc=rss",
"published": "2026-06-28",
"age_days": 8,
"source": "Yahoo Finance",
"snippet": "Monster Beverage Corporation (NASDAQ:MNST) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 22, 2026, Morgan Stanley said the Beverage Business Insights newsletter confirmed a high-single-digit Red Bull price increase in the U.S. on August 1, which the firm views as positive for sustained category and Monster Beverage Corporation […]",
"relevance": 2.3,
"category": "业绩/指引",
"sentiment": "positive",
"freshness": 0.65,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "Monster Beverage (MNST) Stock After 47% Yearly Gain Is The Price Still Attractive",
"link": "https://finance.yahoo.com/markets/stocks/articles/monster-beverage-mnst-stock-47-221207381.html?.tsrc=rss",
"published": "2026-06-23",
"age_days": 12,
"source": "Yahoo Finance",
"snippet": "Some investors may be wondering whether Monster Beverage is still worth considering at around US$93.69, or if most of the easy upside is already reflected in the price. The stock has posted returns of 0.8% over the past week, 8.0% over the past month, 23.0% year to date, and 47.4% over the last year, which has put valuation firmly on many investors' radar. Recent headlines around Monster Beverage have focused on the company's position in the energy drink market and ongoing product and...",
"relevance": 2.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
}
],
"news_score": 0.9630000000000001,
"positive_hits": 3.65,
"negative_hits": 0.0,
"news_sources": [
"BNK Invest",
"Investing.com",
"TIKR.com",
"The Motley Fool",
"Yahoo Finance"
],
"catalysts": [
"分析师/评级",
"市场观点"
],
"news_errors": []
},
{
"symbol": "CAT",
"name": "Caterpillar Inc. Common Stock",
"sector": "Industrials",
"industry": "Construction/Ag Equipment/Trucks",
"exchange": "NYSE",
"market_cap": 443837593662.0,
"dollar_volume": 3438147718.99,
"price": 963.530029296875,
"last_date": "2026-07-02",
"return_5d": -0.08843812225532066,
"return_20d": 0.04032697414806763,
"return_60d": 0.3300342692972793,
"return_120d": 0.584414552086685,
"ma20_distance": 7.94318881347511e-05,
"ma50_distance": 0.0552172225958143,
"ma200_distance": 0.38282515884112955,
"volume_ratio": 1.5760803680929545,
"volatility_20d": 0.5946452908805241,
"drawdown_52w": -0.09519203004334997,
"trend_score": 1.0,
"sector_score": 0.5384615384615384,
"rs_20d": 0.05286934933366394,
"rs_60d": 0.11934441205829494,
"entry_setup_score": 1.0,
"overheat_score": 0.0,
"breakdown": {
"technical": 20.391050583657588,
"relative_strength": 12.77431906614786,
"volume": 10.785992217898833,
"sector": 5.384615384615384,
"news": 16.0,
"liquidity": 9.377431906614786,
"risk_quality": 4.795719844357976,
"entry_setup": 8.0,
"overheat_penalty": -0.0
},
"score": 79.50912900329243,
"items": [
{
"title": "Caterpillar (CAT) Launches $100 Million Texas Workforce Push For Advanced Manufacturing",
"link": "https://finance.yahoo.com/markets/stocks/articles/caterpillar-cat-launches-100-million-070839952.html?.tsrc=rss",
"published": "2026-07-06",
"age_days": 0,
"source": "Yahoo Finance",
"snippet": "Caterpillar launched a five year, $100 million Building the Future Workforce Initiative in Texas focused on advanced manufacturing and industry technician roles. The program is designed to expand training, education, and talent pipelines in key Texan communities where Caterpillar operates. This workforce investment adds a fresh dimension to recent conversations about NYSE:CAT that have centered on index inclusion, valuation, and sentiment. Caterpillar, traded as NYSE:CAT, is putting...",
"relevance": 1.6500000000000001,
"category": "产品/订单",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "Caterpillar (CAT) is a Great Momentum Stock: Should You Buy?",
"link": "https://finance.yahoo.com/markets/stocks/articles/caterpillar-cat-great-momentum-stock-160002957.html?.tsrc=rss",
"published": "2026-07-03",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "Does Caterpillar (CAT) have what it takes to be a top stock pick for momentum investors? Let's find out.",
"relevance": 2.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Is Caterpillar (CAT) a Buy as Wall Street Analysts Look Optimistic?",
"link": "https://finance.yahoo.com/markets/stocks/articles/caterpillar-cat-buy-wall-street-133006257.html?.tsrc=rss",
"published": "2026-07-03",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "Based on the average brokerage recommendation (ABR), Caterpillar (CAT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
"relevance": 2.0,
"category": "分析师/评级",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Why Caterpillar (CAT) is a Top Stock for the Long-Term",
"link": "https://www.nasdaq.com/articles/why-caterpillar-cat-top-stock-long-term-3",
"published": "2026-07-03",
"age_days": 3,
"source": "Zacks",
"snippet": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.",
"relevance": 1.7,
"category": "市场观点",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 2.0,
"negative_hits": 0.0
},
{
"title": "Dow Hits 21st All-Time Closing High in 2026: Buy These 3 Stocks",
"link": "https://www.nasdaq.com/articles/dow-hits-21st-all-time-closing-high-2026-buy-these-3-stocks",
"published": "2026-07-03",
"age_days": 3,
"source": "Zacks",
"snippet": "Dow hits its 21st record close of 2026 as investors rotate into defensive blue chips, spotlighting GS, CAT and KO for their earnings growth potential.",
"relevance": 1.35,
"category": "业绩/指引",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 2.0,
"negative_hits": 0.0
},
{
"title": "Caterpillar (CAT) Stock Faces Michael Burry Short As Valuation Questions Grow",
"link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQemlEOHJ5cC1PanFfUnc5QXFUSjkzNUp3YmdhaDFIcVFHS2NJYmdqNGVyZjAyWDFxSC1QeDNhTUpRM0FCWUlYN28wcng1QVNLUFRmRWVCczBILVlkMHo4enpzNktYWXVhUUNJQi1nUmxXenlWOEFZa2JmdUIwN0dZMmczdzFzRm0zY3VDYl8wQWk2VjBUQlk3ekl1WlJjZjNSVEE?oc=5",
"published": "2026-07-02",
"age_days": 4,
"source": "Yahoo Finance",
"snippet": "Caterpillar (CAT) Stock Faces Michael Burry Short As Valuation Questions Grow Yahoo Finance",
"relevance": 2.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Michael Burry says he's shorting Caterpillar for the first time after it nearly doubled in the AI-driven rally of 2026",
"link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOcnl6cXZ3b0cxZEJFTFJSNW9ySGpXalVsZldLbGJzQmF0aWRDQXNIdWd1V2l5Mk9rdVVjcnFUNVdwUE80bEhKLWs3T0k3VkJuemxyc2c3TTJ5bWlicDQyeFI0R09GcmNzVU5yQUFBbWR5aTFuM0lqTjdhUWR0ZE1hRVBsVV95LXFsMTJwZndHcjdkTThXS3JrSTh3WVhJVk9TVHFNT2h0UWLSAa4BQVVfeXFMUExNcjJHZDZQbHVuUllfdnhqUl9wZUQyejNJWTVaS0VZeWw1LXBFbGU3aXVSU0ZxM1lqUG9nLTYtZjFKbF8zT1NadHo0YnRwcnM4cFpLaEhfLU5SQ0ZNeXBFajM0aVN0M3I0eUFDNTdkZV9SaWx5NHZXODM5NV9lazlvQWxnR0R1a2d3X2VVWWQ4WWs3U1NTMmZ4TFRfUC1vRXl5X1pHNkVycFlDc2ln?oc=5",
"published": "2026-06-30",
"age_days": 5,
"source": "CNBC",
"snippet": "Michael Burry says he's shorting Caterpillar for the first time after it nearly doubled in the AI-driven rally of 2026 CNBC",
"relevance": 1.35,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "How CAT Stock Doubles Again To Reach $2,000",
"link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNVF9tZlBFNlRDZGwyQy1BRmhqNGdqM3c0V284R3NuMGF0aVp3dm4tZ1ZqTG5ndWNjcGdKNkI5VjZVSk9mcGxBZkZvVjYtRzNTcVJTTzBIYmN3eEdHMHk3RmNEem1ZVGFkdXJmVW1kWWhfYndDYUVLdjBCMkpJRi1YNVBNZ0pGVjJHbjNKQmd6NHZCTlB3ZVozTl9Ednc2NjJ6cUVz?oc=5",
"published": "2026-06-26",
"age_days": 10,
"source": "Trefis",
"snippet": "How CAT Stock Doubles Again To Reach $2,000 Trefis",
"relevance": 1.35,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Why Has Caterpillar Stock Soared 184% in the Last 12 Months?",
"link": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQWjVPREJnWTd5bHB3WTFHZVFiUS00SnIwS3JMSVhtWDk5N0c1bEFBUVh4eHV6TGVhQ0JQUlJKWVJZVkhBTnB6YkFDWUhIaEJqTmx6LVFfRjZMTi16Q0d4MzAzNUJDZlZIVlVYQmw2REdOY2FnQjB3dlBIMTVhWnQ4VnFUWERObUVXQU1VU0FSX2d0S2hxSk5uVA?oc=5",
"published": "2026-06-24",
"age_days": 12,
"source": "The Motley Fool",
"snippet": "Why Has Caterpillar Stock Soared 184% in the Last 12 Months? The Motley Fool",
"relevance": 1.7,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
}
],
"news_score": 1.0,
"positive_hits": 5.0,
"negative_hits": 0.0,
"news_sources": [
"CNBC",
"The Motley Fool",
"Trefis",
"Yahoo Finance",
"Zacks"
],
"catalysts": [
"业绩/指引",
"产品/订单",
"分析师/评级",
"市场观点"
],
"news_errors": []
},
{
"symbol": "GE",
"name": "GE Aerospace Common Stock",
"sector": "Technology",
"industry": "Consumer Electronics/Appliances",
"exchange": "NYSE",
"market_cap": 393880672957.0,
"dollar_volume": 1236262101.36,
"price": 377.5199890136719,
"last_date": "2026-07-02",
"return_5d": 0.01658768824077206,
"return_20d": 0.19984735392125264,
"return_60d": 0.3081080423756548,
"return_120d": 0.20061056507598818,
"ma20_distance": 0.07535791444087736,
"ma50_distance": 0.18371689429071392,
"ma200_distance": 0.22014022767999153,
"volume_ratio": 1.0266253806111951,
"volatility_20d": 0.2952310539825125,
"drawdown_52w": 0.0,
"trend_score": 1.0,
"sector_score": 0.46153846153846156,
"rs_20d": 0.21238972910684895,
"rs_60d": 0.09741818513667044,
"entry_setup_score": 0.9653466938059315,
"overheat_score": 0.0,
"breakdown": {
"technical": 22.238337752782083,
"relative_strength": 15.19260700389105,
"volume": 4.2957198443579765,
"sector": 4.615384615384616,
"news": 16.0,
"liquidity": 8.073929961089494,
"risk_quality": 8.424124513618677,
"entry_setup": 7.722773550447452,
"overheat_penalty": -0.0
},
"score": 78.8401036911239,
"items": [
{
"title": "GE Aerospace or Lockheed Martin: Which Aerospace and Defense Stock Is a Better Buy for 2026?",
"link": "https://www.fool.com/coverage/better-buy/2026/07/04/ge-aerospace-or-lockheed-martin-which-aerospace-and-defense-stock-is-a-better-buy-for-2026/?.tsrc=rss",
"published": "2026-07-04",
"age_days": 1,
"source": "Yahoo Finance",
"snippet": "GE Aerospace posts robust margin gains and surging commercial aviation growth, while Lockheed Martin leans on defense contracts and lower valuations.",
"relevance": 2.0,
"category": "产品/订单",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 2.0,
"negative_hits": 0.0
},
{
"title": "Can GE Aerospace Sustain Growth as Commercial Aerospace Demand Surges?",
"link": "https://finance.yahoo.com/markets/stocks/articles/ge-aerospace-sustain-growth-commercial-155300331.html?.tsrc=rss",
"published": "2026-07-03",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "GE's commercial aerospace business is fueling growth with surging engine orders, strong services demand and major manufacturing investments for 2026.",
"relevance": 1.6500000000000001,
"category": "产品/订单",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 3.0,
"negative_hits": 0.0
},
{
"title": "Why GE Aerospace Stock Can Keep Flying",
"link": "https://finance.yahoo.com/m/dbbbcfd1-9dee-37cc-b5a3-23a03345db5a/why-ge-aerospace-stock-can.html?.tsrc=rss",
"published": "2026-07-02",
"age_days": 3,
"source": "Yahoo Finance",
"snippet": "GE Aerospace stock has rebounded nicely from a post-Iran war slump. On Wednesday, Citi analyst John Godyn raised his GE Aerospace price target by 22% to $431 a share from $353. GE stock rose $0.7%, closing at $377.52.",
"relevance": 2.0,
"category": "分析师/评级",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "Get Paid 8.1% A Year To Hold RTX Stock You Already Own",
"link": "https://www.trefis.com/articles/605516/get-paid-8-1-a-year-to-hold-rtx-stock-you-already-own/2026-07-02?.tsrc=rss",
"published": "2026-07-02",
"age_days": 3,
"source": "Yahoo Finance",
"snippet": "Here is a way to get paid a meaningful income right now on your RTX shares, an income you keep no matter what, in exchange for agreeing to sell at a price above today's.",
"relevance": 1.6500000000000001,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Will GE Vernova (GEV) Beat Estimates Again in Its Next Earnings Report?",
"link": "https://finance.yahoo.com/markets/stocks/articles/ge-vernova-gev-beat-estimates-161004422.html?.tsrc=rss",
"published": "2026-07-02",
"age_days": 3,
"source": "Yahoo Finance",
"snippet": "GE Vernova (GEV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
"relevance": 1.3,
"category": "业绩/指引",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "GE Vernova's gas turbines aren't the only way it's winning from the AI boom",
"link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNWDIyYS1VSzI2OGZ0QzNEZTlSaDNUS3NLQS15Z1hNY2lEV2xPbUNUb2xmM0FCRFJFSWE5eFlXVFphZGVRelVaNmdmN05JczFTY1pJNE52c09kMUMwMGdMRDZrMnNPeGZ2bHFBU1BVS0RNV1AwM2toU19rV05McjRDNjc0NnBKdFQ1ZjR5dmNOWndya1VmN1dnYlRNT2x3azJjRGM1Q0EtSTAxYnJ6b3c?oc=5",
"published": "2026-07-02",
"age_days": 3,
"source": "CNBC",
"snippet": "GE Vernova's gas turbines aren't the only way it's winning from the AI boom CNBC",
"relevance": 1.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Is GE’s Tightened Governance And Dividend Policy Quietly Reframing The Investment Case For General Electric (GE)?",
"link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPeTRIblIxUXBLZ0pfc295NGV4S3ZRbDFhR3pDX3VvWkRFVjhyd2ZyakZpTlRRWG5wdTNDR2RTRnZFQ19kU0tVYWlLazAzOWwyM1V5cmN4dF9DUFZDcjJmMnVSN0l3MzZkVlhkQWl4cUV0dDhDWDNDRTdsU0JYcXY2U2d3VVZnM2llYjBFdmJwMlVadEZ4aEl3M2lsa3BPMkZrcE5KMVl1WQ?oc=5",
"published": "2026-07-02",
"age_days": 4,
"source": "Yahoo Finance",
"snippet": "Is GE’s Tightened Governance And Dividend Policy Quietly Reframing The Investment Case For General Electric (GE)? Yahoo Finance",
"relevance": 1.3,
"category": "并购/资本",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "This Hidden Aerospace Stock Is Up 470% in the Last 5 Years and Just Hit a New All-Time High",
"link": "https://www.nasdaq.com/articles/hidden-aerospace-stock-470-last-5-years-and-just-hit-new-all-time-high",
"published": "2026-07-01",
"age_days": 5,
"source": "The Motley Fool",
"snippet": "Key PointsGE Aerospace is one of the three “old” General Electric stocks.",
"relevance": 1.7,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Why GE (GE) is Poised to Beat Earnings Estimates Again",
"link": "https://www.nasdaq.com/articles/why-ge-ge-poised-beat-earnings-estimates-again",
"published": "2026-07-01",
"age_days": 5,
"source": "Zacks",
"snippet": "GE (GE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
"relevance": 1.0,
"category": "业绩/指引",
"sentiment": "positive",
"freshness": 0.65,
"positive_hits": 1.0,
"negative_hits": 0.0
}
],
"news_score": 1.0,
"positive_hits": 7.65,
"negative_hits": 0.0,
"news_sources": [
"CNBC",
"The Motley Fool",
"Yahoo Finance",
"Zacks"
],
"catalysts": [
"业绩/指引",
"产品/订单",
"分析师/评级",
"市场观点"
],
"news_errors": []
},
{
"symbol": "PTCT",
"name": "PTC Therapeutics Inc. Common Stock",
"sector": "Health Care",
"industry": "Biotechnology: Pharmaceutical Preparations",
"exchange": "NASDAQ",
"market_cap": 6910509349.0,
"dollar_volume": 564634608.03,
"price": 83.30999755859375,
"last_date": "2026-07-02",
"return_5d": -0.014199556825265525,
"return_20d": 0.21301684898675566,
"return_60d": 0.1973267514547714,
"return_120d": 0.08405984661988031,
"ma20_distance": 0.06729011157550335,
"ma50_distance": 0.14065157953302942,
"ma200_distance": 0.1671368885208886,
"volume_ratio": 1.7204537805265905,
"volatility_20d": 0.3870554430941394,
"drawdown_52w": -0.034086984827898514,
"trend_score": 1.0,
"sector_score": 0.8461538461538461,
"rs_20d": 0.22555922417235197,
"rs_60d": -0.013363105784212959,
"entry_setup_score": 0.9514458103135945,
"overheat_score": 0.0,
"breakdown": {
"technical": 21.644640412469847,
"relative_strength": 14.04669260700389,
"volume": 11.11284046692607,
"sector": 8.461538461538462,
"news": 11.012,
"liquidity": 5.447470817120622,
"risk_quality": 6.760700389105059,
"entry_setup": 7.611566482508756,
"overheat_penalty": -0.0
},
"score": 78.48588315416393,
"items": [
{
"title": "Ptc therapeutics chief technical ops officer sells $693k in stock",
"link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOdFJTME42bE5JODBzMTNPdllRZXRyQkFkcGRveHl3R3F3d0VyUVc3OWVDNFNJZjJ2d1Ixa0NPcHNPVFYzVldIdEdUUlo3SmpBWGNmZWtzc2pqOURQOVZhT2pUTi1lYmlBcmlUczFHdUR0X0lMeHZrZ3ZNS0hyXzBCWXZQd1RtY3U3enhiMlhfWVV4SWkzTVlMWkE1VmZYVWdFdEkxeE50cVNMdV9LUHNVNXAxYXZDQm1XVmhNdlNXVnlYSEhua1hPdQ?oc=5",
"published": "2026-06-30",
"age_days": 5,
"source": "Investing.com",
"snippet": "Ptc therapeutics chief technical ops officer sells $693k in stock Investing.com",
"relevance": 0.7,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "The Prognosis For PTC Therapeutics (NASDAQ:PTCT)",
"link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOd3RSUWlMLWR5ajlDazNHWk1OUWN2NzgwUHNHeFZiQWhuclBudXctcG5ObGVTTjZURldscTVNQTUzZlBWNEJ1YUFMMmZxUjNzbWI5eFI1RHYwSXRJZWNSUExkUm1uSThQdU1wZUNPNlk1RU5jdUgxYjJzWHJiaWdjNw?oc=5",
"published": "2026-06-23",
"age_days": 13,
"source": "Seeking Alpha",
"snippet": "The Prognosis For PTC Therapeutics (NASDAQ:PTCT) Seeking Alpha",
"relevance": 1.35,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?",
"link": "https://finance.yahoo.com/markets/stocks/articles/ptc-therapeutics-ptct-moves-7-121600735.html?.tsrc=rss",
"published": "2026-06-18",
"age_days": 17,
"source": "Yahoo Finance",
"snippet": "PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.",
"relevance": 1.6500000000000001,
"category": "业绩/指引",
"sentiment": "positive",
"freshness": 0.3,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
"link": "https://finance.yahoo.com/healthcare/articles/ptc-therapeutics-reports-inducement-grants-203000052.html?.tsrc=rss",
"published": "2026-06-17",
"age_days": 18,
"source": "Yahoo Finance",
"snippet": "PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock and 11,870 restricted stock units (\"RSUs\"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.",
"relevance": 2.3,
"category": "市场观点",
"sentiment": "positive",
"freshness": 0.3,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "PTC Therapeutics (PTCT) Stock Could Be 14% Undervalued After $500 Million Note Refinancing",
"link": "https://news.google.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?oc=5",
"published": "2026-06-18",
"age_days": 18,
"source": "simplywall.st",
"snippet": "PTC Therapeutics (PTCT) Stock Could Be 14% Undervalued After $500 Million Note Refinancing simplywall.st",
"relevance": 1.7,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes",
"link": "https://finance.yahoo.com/healthcare/articles/ptc-therapeutics-announces-pricing-convertible-031400518.html?.tsrc=rss",
"published": "2026-06-16",
"age_days": 20,
"source": "Yahoo Finance",
"snippet": "PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the pricing of $500.0 million aggregate principal amount of 0% Convertible Senior Notes due 2031 (the \"Notes\") in a private placement (the \"Offering\") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the \"Securities Act\"). PTC also granted the initial purchasers an option to purchase, within the 13-day period beginning on, and including, the date on which the Notes are first issued, up to",
"relevance": 1.6500000000000001,
"category": "监管/法律",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes",
"link": "https://finance.yahoo.com/markets/stocks/articles/ptc-therapeutics-announces-proposed-convertible-110000051.html?.tsrc=rss",
"published": "2026-06-15",
"age_days": 20,
"source": "Yahoo Finance",
"snippet": "PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the \"Notes\") in a private placement (the \"Offering\") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the \"Securities Act\"). PTC intends to grant the initial purchasers an option to purchase, within a 13-day period beginning on, and inclu",
"relevance": 1.6500000000000001,
"category": "监管/法律",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "PTC Therapeutics Prices $500 Mln Convertible Notes Concurrently With 2026 Note Repurchase",
"link": "https://www.nasdaq.com/articles/ptc-therapeutics-prices-500-mln-convertible-notes-concurrently-2026-note-repurchase",
"published": "2026-06-16",
"age_days": 20,
"source": "RTTNews",
"snippet": "(RTTNews) - PTC Therapeutics, Inc. (PTCT) announced the pricing of a $500 million offering of convertible senior notes due 2031 in a Rule 144A private placement to qualified institutional buyers. The notes carry an initial conversion price of approximately $107.48 per share, repr",
"relevance": 1.35,
"category": "并购/资本",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "PTCT Stock In Focus As $500M Convertible Notes Meet Insider Sale",
"link": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQSnhaZnhQUk9hWVE3RVVaajFRcFlGUWpvR2pmZ3UzMUFIQlJuV1pETE5DMS04SnJMWkZjWHZBWDZ6WTkzUHpXdGhFYUlONXFvUmZNVzlvMUNaMHplTURIaUVFb2J1WFZCcmlrQUV4ZmNBSVEyd3JPdzdFcFFIakd6bFpn?oc=5",
"published": "2026-06-16",
"age_days": 20,
"source": "timothysykes.com",
"snippet": "PTCT Stock In Focus As $500M Convertible Notes Meet Insider Sale timothysykes.com",
"relevance": 1.35,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.3,
"positive_hits": 0.0,
"negative_hits": 0.0
}
],
"news_score": 0.68825,
"positive_hits": 0.6,
"negative_hits": 0.0,
"news_sources": [
"Investing.com",
"RTTNews",
"Seeking Alpha",
"Yahoo Finance",
"simplywall.st",
"timothysykes.com"
],
"catalysts": [
"业绩/指引",
"市场观点"
],
"news_errors": []
},
{
"symbol": "CRS",
"name": "Carpenter Technology Corporation Common Stock",
"sector": "Industrials",
"industry": "Steel/Iron Ore",
"exchange": "NYSE",
"market_cap": 29674234911.0,
"dollar_volume": 399523100.76,
"price": 597.239990234375,
"last_date": "2026-07-02",
"return_5d": -0.003337560964877806,
"return_20d": 0.22623961647288837,
"return_60d": 0.5158375386659264,
"return_120d": 0.8590548841422592,
"ma20_distance": 0.05684401239622283,
"ma50_distance": 0.22158249401943686,
"ma200_distance": 0.6028307704971088,
"volume_ratio": 1.4466830544511806,
"volatility_20d": 0.3779796448202495,
"drawdown_52w": -0.031774910459379524,
"trend_score": 1.0,
"sector_score": 0.5384615384615384,
"rs_20d": 0.23878199165848468,
"rs_60d": 0.30514768142694204,
"entry_setup_score": 0.8297013758450824,
"overheat_score": 0.0063299760777474345,
"breakdown": {
"technical": 21.690140189640037,
"relative_strength": 16.24124513618677,
"volume": 10.01556420233463,
"sector": 5.384615384615384,
"news": 14.624,
"liquidity": 3.501945525291829,
"risk_quality": 6.794676892919024,
"entry_setup": 6.637611006760659,
"overheat_penalty": -0.06329976077747435
},
"score": 78.18888757021021,
"items": [
{
"title": "Will Carpenter (CRS) Beat Estimates Again in Its Next Earnings Report?",
"link": "https://finance.yahoo.com/markets/stocks/articles/carpenter-crs-beat-estimates-again-161002889.html?.tsrc=rss",
"published": "2026-07-03",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "Carpenter (CRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
"relevance": 1.6500000000000001,
"category": "业绩/指引",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "If You Invested $1000 in Carpenter Technology a Decade Ago, This is How Much It'd Be Worth Now",
"link": "https://finance.yahoo.com/markets/stocks/articles/invested-1000-carpenter-technology-decade-123001896.html?.tsrc=rss",
"published": "2026-07-03",
"age_days": 2,
"source": "Yahoo Finance",
"snippet": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
"relevance": 1.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Carpenter Technology (CRS) director awarded new deferred stock units",
"link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQYVVZbVdBdjdtOVlzd2dBa3pPZXZSZ1JuejllV0RKZHZFbUNwTVVmZllkUGVDckp1LWhNckhrbVVib0oxY3lVcVpvRFdGMnRxTTM4UFZ6ZTA5bk9kVVFiUGxqUVZnNkFTQ0g0VkZ4N2IxUzN6a2d2Qk02SUpzODBCcmFudUFtTlg0UlNBUExCZ0tGZEd0U2dETUhYeW1HZ2NaRXdaRnVyNW1Dd3ZJNzQyT1VJX3Z1Y2JDYVE?oc=5",
"published": "2026-07-02",
"age_days": 3,
"source": "Stock Titan",
"snippet": "Carpenter Technology (CRS) director awarded new deferred stock units Stock Titan",
"relevance": 1.7,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Carpenter Technology Announces Conference Call and Webcast",
"link": "https://finance.yahoo.com/markets/stocks/articles/carpenter-technology-announces-conference-call-130000003.html?.tsrc=rss",
"published": "2026-07-01",
"age_days": 4,
"source": "Yahoo Finance",
"snippet": "PHILADELPHIA, July 01, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) plans to host a conference call and webcast on Thursday, July 30, 2026 at 10:00 a.m. ET to discuss the results of operations for the fourth quarter of fiscal year 2026, ended June 30, 2026. The call and webcast will follow the release of fourth quarter fiscal 2026 financial results before the market opens on Thursday, July 30, 2026. Conference Call and Webcast Details What: Carpenter Technology Fourth Qu",
"relevance": 2.3,
"category": "业绩/指引",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Aerospace Demand Recovery Fuels Carpenter Technology Corp.’s (CRS) Strength",
"link": "https://finance.yahoo.com/markets/stocks/articles/aerospace-demand-recovery-fuels-carpenter-134239358.html?.tsrc=rss",
"published": "2026-07-01",
"age_days": 4,
"source": "Yahoo Finance",
"snippet": "TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Strategy fell 7.72% (net) in the quarter compared to -6.35% for the Russell Midcap Growth Index. In the first quarter, markets navigated geopolitical tensions and economic resilience alongside […]",
"relevance": 2.0,
"category": "业绩/指引",
"sentiment": "positive",
"freshness": 0.65,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "3 Reasons Why Growth Investors Shouldn't Overlook Carpenter (CRS)",
"link": "https://finance.yahoo.com/markets/stocks/articles/3-reasons-why-growth-investors-164507108.html?.tsrc=rss",
"published": "2026-06-30",
"age_days": 5,
"source": "Yahoo Finance",
"snippet": "Carpenter (CRS) is well positioned to outperform the market, as it exhibits above-average growth in financials.",
"relevance": 1.6500000000000001,
"category": "分析师/评级",
"sentiment": "positive",
"freshness": 0.65,
"positive_hits": 2.0,
"negative_hits": 0.0
},
{
"title": "Notable ETF Outflow Detected - IJH, CRS, TWLO, ATI",
"link": "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ijh-crs-twlo-ati",
"published": "2026-06-30",
"age_days": 6,
"source": "BNK Invest",
"snippet": "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Mid-Cap ETF (Symbol: IJH) where we have detected an approximate $1.7 billion dollar outflow -- that's a 1.4% decrease week over",
"relevance": 1.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Are You Looking for a Top Momentum Pick? Why Carpenter Technology (CRS) is a Great Choice",
"link": "https://finance.yahoo.com/markets/stocks/articles/looking-top-momentum-pick-why-160004735.html?.tsrc=rss",
"published": "2026-06-26",
"age_days": 9,
"source": "Yahoo Finance",
"snippet": "Does Carpenter Technology (CRS) have what it takes to be a top stock pick for momentum investors? Let's find out.",
"relevance": 2.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "CRS Forecast — Price Target — Prediction for 2027",
"link": "https://news.google.com/rss/articles/CBMidkFVX3lxTE0tVDBjSEk0RDg2bW9MSUNsc3Fvd1JWM082SlVSZUhvcS1DcHNodFEtajFmeXJwNUlTNXFvcmtLcFBxMGx5MFRTRVFsdEJCdzdXRV9RUHVPRXZsMWpRc2xaN2xZbWZVcnNwbXV1WEZMc3pUZGVnM3c?oc=5",
"published": "2026-06-26",
"age_days": 9,
"source": "TradingView",
"snippet": "CRS Forecast — Price Target — Prediction for 2027 TradingView",
"relevance": 1.0,
"category": "分析师/评级",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
}
],
"news_score": 0.914,
"positive_hits": 2.95,
"negative_hits": 0.0,
"news_sources": [
"BNK Invest",
"Stock Titan",
"TradingView",
"Yahoo Finance"
],
"catalysts": [
"业绩/指引",
"市场观点"
],
"news_errors": []
},
{
"symbol": "JNJ",
"name": "Johnson & Johnson Common Stock",
"sector": "Health Care",
"industry": "Biotechnology: Pharmaceutical Preparations",
"exchange": "NYSE",
"market_cap": 633194352052.0,
"dollar_volume": 2103974102.4,
"price": 263.0400085449219,
"last_date": "2026-07-02",
"return_5d": 0.07415878511926621,
"return_20d": 0.17828347102856767,
"return_60d": 0.10330944383407581,
"return_120d": 0.2784447559898997,
"ma20_distance": 0.09108333673929181,
"ma50_distance": 0.13021056722933544,
"ma200_distance": 0.20145142589496756,
"volume_ratio": 1.1284449912341787,
"volatility_20d": 0.27971794563776875,
"drawdown_52w": 0.0,
"trend_score": 1.0,
"sector_score": 0.8461538461538461,
"rs_20d": 0.19082584621416399,
"rs_60d": -0.10738041340490856,
"entry_setup_score": 1.0,
"overheat_score": 0.0,
"breakdown": {
"technical": 20.920233463035018,
"relative_strength": 11.80350194552529,
"volume": 5.883268482490272,
"sector": 8.461538461538462,
"news": 13.448,
"liquidity": 8.8715953307393,
"risk_quality": 8.540856031128405,
"entry_setup": 8.0,
"overheat_penalty": -0.0
},
"score": 77.92899371445674,
"items": [
{
"title": "Johnson & Johnson (JNJ) Unveils New IMAAVY Data With Broader Reach In View",
"link": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-unveils-imaavy-190746379.html?.tsrc=rss",
"published": "2026-07-05",
"age_days": 0,
"source": "Yahoo Finance",
"snippet": "Johnson & Johnson (NYSE:JNJ) presented new real-world and clinical data on IMAAVY (nipocalimab-aahu) for generalized myasthenia gravis at the European Academy of Neurology Congress. The data highlighted improved outcomes in patients treated earlier in their disease course and sustained symptom control even after common infections. Additional pregnancy safety monitoring and ongoing trials point to potential use in hard-to-treat and at-risk patient groups beyond the current label. For...",
"relevance": 2.3,
"category": "医药/审批",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Johnson & Johnson (JNJ) Is One Of Jim Cramer’s Top Performing 2026 Stocks",
"link": "https://finance.yahoo.com/markets/stocks/articles/johnson-johnson-jnj-one-jim-111255929.html?.tsrc=rss",
"published": "2026-07-05",
"age_days": 0,
"source": "Yahoo Finance",
"snippet": "We recently published Jim Cramer’s Biggest Winners to Buy: Top 20 AI & Other Stocks He Got Right in 2026. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer. Healthcare giant Johnson & Johnson (NYSE:JNJ)’s shares are up by 68% over the past year and by 26% year-to-date. The firm reported […]",
"relevance": 2.3,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "NAVN, JNJ, CRWD Stocks Hit 52-Week Highs Last Week: What's Driving The Surge?",
"link": "https://stocktwits.com/news-articles/markets/equity/navn-jnj-crwd-stocks-hit-52-week-highs-last-week-what-s-driving-the-surge/cZmKzcAR7kn?.tsrc=rss",
"published": "2026-07-06",
"age_days": 0,
"source": "Yahoo Finance",
"snippet": "Investors continued to pump money into select companies backed by business developments rather than broad market trends.",
"relevance": 1.6500000000000001,
"category": "市场观点",
"sentiment": "positive",
"freshness": 1.0,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "Johnson & Johnson (JNJ) Stock Looks Undervalued On Cash Flow While Earnings Look Fair",
"link": "https://news.google.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?oc=5",
"published": "2026-07-05",
"age_days": 1,
"source": "simplywall.st",
"snippet": "Johnson & Johnson (JNJ) Stock Looks Undervalued On Cash Flow While Earnings Look Fair simplywall.st",
"relevance": 2.0,
"category": "业绩/指引",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Members of Congress Are Loading Up on Johnson & Johnson and UnitedHealth. Here's Why Retail Investors Should Pay Attention.",
"link": "https://www.nasdaq.com/articles/members-congress-are-loading-johnson-johnson-and-unitedhealth-heres-why-retail-investors",
"published": "2026-07-03",
"age_days": 3,
"source": "The Motley Fool",
"snippet": "Key PointsRep. Lisa McClain (R-Mich.) has been a big buyer of Johnson & Johnson stock.",
"relevance": 1.0,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?",
"link": "https://www.nasdaq.com/articles/johnson-johnson-walking-away-100-billion-obesity-market-could-actually-make-it-better-long",
"published": "2026-07-03",
"age_days": 3,
"source": "The Motley Fool",
"snippet": "Key PointsJohnson & Johnson's CEO recently explained that his company isn't going to get caught up in the GLP-1 weight loss drug race.",
"relevance": 0.7,
"category": "医药/审批",
"sentiment": "neutral",
"freshness": 1.0,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?",
"link": "https://www.nasdaq.com/articles/it-worth-investing-johnson-johnson-jnj-based-wall-streets-bullish-views",
"published": "2026-07-02",
"age_days": 4,
"source": "Zacks",
"snippet": "According to the average brokerage recommendation (ABR), one should invest in Johnson & Johnson (JNJ). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
"relevance": 2.0,
"category": "分析师/评级",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
},
{
"title": "J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?",
"link": "https://www.nasdaq.com/articles/jj-or-abbvie-which-stock-deserves-place-your-portfolio-now",
"published": "2026-07-02",
"age_days": 4,
"source": "Zacks",
"snippet": "JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.",
"relevance": 1.35,
"category": "市场观点",
"sentiment": "positive",
"freshness": 0.65,
"positive_hits": 1.0,
"negative_hits": 0.0
},
{
"title": "Johnson & Johnson (JNJ) Stock After 73% One-Year Rally Is There Value Left",
"link": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNMXRiN0hmU0xUMUpjVDVzTXAtZ2xOZHZpdENrWW9FMFhyMUJHVmVkY1l5V05WY0dqX1E2UnRhTUxNR0FfZExuNGNJdUlQNDNlcE5pQUtQNVVsN0NiazhJbXRzdXMxT2VPcWpEOGVBY213V2xEZHNfckpZTkpLWDZhNGJiZ3Nfc0pCbzIzcFVzVzBZdXFWNXZxUw?oc=5",
"published": "2026-06-30",
"age_days": 5,
"source": "Yahoo Finance",
"snippet": "Johnson & Johnson (JNJ) Stock After 73% One-Year Rally Is There Value Left Yahoo Finance",
"relevance": 2.3,
"category": "市场观点",
"sentiment": "neutral",
"freshness": 0.65,
"positive_hits": 0.0,
"negative_hits": 0.0
}
],
"news_score": 0.8405,
"positive_hits": 1.65,
"negative_hits": 0.0,
"news_sources": [
"The Motley Fool",
"Yahoo Finance",
"Zacks",
"simplywall.st"
],
"catalysts": [
"业绩/指引",
"医药/审批",
"市场观点"
],
"news_errors": []
}
],
"sources": [
"Nasdaq screener: exchange, sector, market cap, latest price and volume",
"Yahoo Finance chart endpoint: daily prices and volume",
"Yahoo Finance RSS: recent company headlines",
"Nasdaq news API: publisher, headline, and company-specific news snippets",
"Google News RSS: broader company/ticker news discovery"
]
}